Vivek Subbiah: Precision Medicine for FGFR in bladder cancer has now arrived

Vivek Subbiah shared on X/Twitter:

“Just published Annals of Oncology. Pleased to share our editorial “Unlocking precision oncology with FGFR inhibition in urothelial carcinoma” spearheaded by GU “Guru” Guru P. Sonpavde

Precision Medicine for FGFR in bladder cancer has now arrived.
Our next steps are to personalize the right treatment to the right patient at the right time perhaps at the right setting with the right combination—all in our overarching endeavor to individualize bladder cancer treatment + extend these practices to broader medical contexts from just incremental steps to paradigm shifts.”

For details click here.
Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.